Inventiva (IVA) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Inventiva is gearing up for its Combined General Meeting on December 11, 2024, where shareholders will vote on crucial resolutions, including a financing plan of up to 348 million euros and the appointment of new directors. The biopharmaceutical company, known for its work on MASH/NASH treatments, is advancing its clinical pipeline, with lanifibranor in a Phase 3 trial and plans for further development activities. This meeting marks a significant step for Inventiva as it navigates its strategic and financial future.
For further insights into IVA stock, check out TipRanks’ Stock Analysis page.
